What does GAIN mean?
GAIN means Glycine Antagonist in Neuroprotection
This acronym/slang usually belongs to Medical & Science category.
What is the abbreviation for Glycine Antagonist in Neuroprotection?
Glycine Antagonist in Neuroprotection can be abbreviated as GAIN
|
|
Most popular questions people look for before coming to this page
Q: A: |
What does GAIN stand for? GAIN stands for "Glycine Antagonist in Neuroprotection". |
Q: A: |
How to abbreviate "Glycine Antagonist in Neuroprotection"? "Glycine Antagonist in Neuroprotection" can be abbreviated as GAIN. |
Q: A: |
What is the meaning of GAIN abbreviation? The meaning of GAIN abbreviation is "Glycine Antagonist in Neuroprotection". |
Q: A: |
What is GAIN abbreviation? One of the definitions of GAIN is "Glycine Antagonist in Neuroprotection". |
Q: A: |
What does GAIN mean? GAIN as abbreviation means "Glycine Antagonist in Neuroprotection". |
Q: A: |
What is shorthand of Glycine Antagonist in Neuroprotection? The most common shorthand of "Glycine Antagonist in Neuroprotection" is GAIN. |
Abbreviations or Slang with similar meaning
- AW - Antagonist Wing
- ANT - Antagonist
- APA - Antagonist Perpetrated Aggression
- 2APV - antagonist 2-amino-5-phosphonovalerate
- AMP - antagonist maintenance program
- AMP - antagonist maintenance programme
- AP5 - antagonist D-2-amino-5-phosphonovalerate
- ARI - antagonist-response interval
- CARE - Calcium Antagonist in Reperfusion
- CNQX - antagonist 6-cyano-7-nitro-quinoxaline-2,3-dione
- CPX - antagonist 8-cyclopentyl-1,3-dipropylxanthine
- CSC - antagonist 8-(3-chlorostyryl)caffeine
- CTOP - antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2
- GGH - Glycine Glycine Histidine
- GPG - glycine, proline, and glycine
- MCPG - antagonist (R,S)-alpha-methyl-4-carboxyphenylglycine
- MPEP - antagonist 2-methyl-6-(phenylethynyl) pyridine hydrochloride
- MPEP - antagonist 2-methyl-6-(phenylethynyl)-pyridine
- NNIPPS - Neuroprotection and Natural history In Parkinson Plus Syndromes: A clinical trial of the efficacy and safety of riluzole in Parkinson plus syndromes
- ADVANCE - a dosing evaluation of a vasopressin antagonist in CHF patients undergoing exercise